TCM
BEAM icon

Tekla Capital Management’s Beam Therapeutics BEAM Stock Holding History

Tekla Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$505K Hold
15,817
– – 0.02% 141
2023
Q1 		$484K Hold
15,817
– – 0.02% 149
2022
Q4 		$619K Hold
15,817
– – 0.02% 143
2022
Q3 		$754K Hold
15,817
– – 0.03% 136
2022
Q2 		$612K Hold
15,817
– – 0.02% 144
2022
Q1 		$906K Hold
15,817
– – 0.03% 148
2021
Q4 		$1.26M Buy
+15,817
New +$1.35M 0.04% 143

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tekla Capital Management's BEAM Position: Q2 2023 in Review

Tekla Capital Management held its Beam Therapeutics (BEAM) position steady in Q2 2023 at 15,817 shares worth $505K. The position accounts for 0.02% of the portfolio, ranked #141.

Tekla Capital Management first reported a position in BEAM in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.26M in Q4 2021. 194 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Tekla Capital Management held 15,817 shares of Beam Therapeutics worth $505K as of Q2 2023.
  • Tekla Capital Management left its Beam Therapeutics share count unchanged in Q2 2023.
  • Beam Therapeutics made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #141 holding.
  • Tekla Capital Management first reported a position in Beam Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • Tekla Capital Management's Beam Therapeutics position peaked at $1.26M in Q4 2021.
  • 194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.